Heart drug vyndaqel tracked in Real-World study
NCT ID NCT04108091
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study looked at how safe and effective Vyndaqel is for people with a rare heart condition called transthyretin amyloid cardiomyopathy. Over 1,200 patients in Japan were followed while taking the drug in regular medical practice. The main goal was to track side effects and survival rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1,214 people
The number who actually took part.
- Started
-
Oct 2019
- Finished
-
Mar 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who are administered with this drug for the treatment of ATTR-CM
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients administered Vyndaqel for the treatment of ATTR-CM Exclusion Criteria: * N/A
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Transthyretin (TTR) amyloid cardiomyopathy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.